Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV002491533 | SCV002789432 | uncertain significance | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2021-09-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002491533 | SCV004568645 | likely benign | Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 | 2024-04-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004986898 | SCV005472854 | uncertain significance | Cardiovascular phenotype | 2024-10-09 | criteria provided, single submitter | clinical testing | The c.4441G>A (p.V1481I) alteration is located in exon 26 (coding exon 26) of the APOB gene. This alteration results from a G to A substitution at nucleotide position 4441, causing the valine (V) at amino acid position 1481 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV004998685 | SCV005624816 | uncertain significance | not provided | 2024-09-21 | criteria provided, single submitter | clinical testing | The APOB c.4441G>A (p.Val1481Ile) variant has not been reported in individuals with APOB-related conditions in the published literature. The frequency of this variant in the general population, 0.000031 (4/128932 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. |